EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells

Connor A Tsuchida, Nadav Brandes, Raymund Bueno, Marena Trinidad, Thomas Mazumder, Bingfei Yu, Byungjin Hwang, Christopher Chang, Jamin Liu, Yang Sun, Caitlin R Hopkins, Kevin R Parker und 11 weitere

Cell · 2023-10 · 186 (21) · 4567-4582.e20

DOI: 10.1016/j.cell.2023.08.041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2023-10. Verfasst von Connor A Tsuchida und 22 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Berkeley-University of California, San Francisco Graduate Program in Bioengineering, University of California, Berkeley, Be…. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Gene Editing, T-Lymphocytes, Chromosome Aberrations. Die Arbeit wurde bisher 215-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NIGMS NIH HHS, Howard Hughes Medical Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced chromosome loss is a universal phenomenon and evaluate its clinical significance, we conducted a systematic analysis in primary human T cells. Arrayed and pooled CRISPR screens revealed that chromosome loss was generalizable across the genome and resulted in partial and entire loss of the targeted chromosome, including in preclinical chimeric antigen receptor T cells. T cells with chromosome loss persisted for weeks in culture, implying the potential to interfere with clinical use. A modified cell manufacturing process, employed in our first-in-human clinical trial of Cas9-engineered T cells (NCT03399448), reduced chromosome loss while largely preserving genome editing efficacy. Expression of p53 correlated with protection from chromosome loss observed in this protocol, suggesting both a mechanism and strategy for T cell engineering that mitigates this genotoxicity in the clinic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGene EditingT-LymphocytesChromosome AberrationsHumansChromosomesDNA DamageClinical Trials as Topic

Stichwörter der Autor:innen

CAR T cellsCRISPR screenCRISPR-Cas9DNA repairT cellsaneuploidychromosome lossclinical trialgenome editingimmunoengineering

Autor:innen und Institutionen

  • University of California, Berkeley-University of California, San Francisco Graduate Program in Bioengineering, University of California, Berkeley, Berkeley, CA, USA; Innovative Genomics Institute, University of Californ…
  • Division of Rheumatology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
  • Center for Personal Dynamic Regulomes, Stanford University, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, Stanford University School of Medicine, Stanford, CA, USA.
  • Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA; Medical Scientist Training Program, University of California, San Francisco, San Francisco, CA, USA; Department of M…
  • University of California, Berkeley-University of California, San Francisco Graduate Program in Bioengineering, University of California, Berkeley, Berkeley, CA, USA; Department of Biochemistry and Biophysics, University…

Förderung

  • NHGRI NIH HHS
  • NIGMS NIH HHS
  • Howard Hughes Medical Institute
  • NIAID NIH HHS
  • NIAMS NIH HHS
  • NCI NIH HHS
  • NHLBI NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Tsuchida, C. A., Brandes, N., Bueno, R., Trinidad, M., Mazumder, T., Yu, B., Hwang, B., Chang, C., Liu, J., Sun, Y., Hopkins, C. R., Parker, K. R., Qi, Y., Hofman, L., Satpathy, A. T., Stadtmauer, E. A., Cate, J. H. D., Eyquem, J., Fraietta, J. A., …, & Doudna, J. A. (2023). Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell, 186(21), 4567-4582.e20. https://doi.org/10.1016/j.cell.2023.08.041

Vancouver

Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 2023;186(21):4567-4582.e20. doi:10.1016/j.cell.2023.08.041

BibTeX
@article{Tsuchida2023,
  author = {Tsuchida, Connor A and Brandes, Nadav and Bueno, Raymund and Trinidad, Marena and Mazumder, Thomas and Yu, Bingfei and Hwang, Byungjin and Chang, Christopher and Liu, Jamin and Sun, Yang and Hopkins, Caitlin R and Parker, Kevin R and Qi, Yanyan and Hofman, Laura and Satpathy, Ansuman T and Stadtmauer, Edward A and Cate, Jamie H D and Eyquem, Justin and Fraietta, Joseph A and June, Carl H and Chang, Howard Y and Ye, Chun Jimmie and Doudna, Jennifer A},
  title = {Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells},
  journal = {Cell},
  year = {2023},
  volume = {186},
  number = {21},
  pages = {4567--4582.e20},
  doi = {10.1016/j.cell.2023.08.041}
}
Kostenlos starten →